Placid Jover Biography and Net Worth

Insider of Teva Pharmaceutical Industries

Placid Jover was appointed Executive Vice President, Chief Human Resources Officer (CHRO) in August 2024. He is responsible for driving Teva's global people strategy, ensuring we have the talent, organizational structure and high-performing culture needed to execute our Pivot to Growth strategy.

As CHRO, Placid heads Teva's global HR team, which collaborates closely with business leaders to enhance organizational performance by aligning people strategies and communications with business objectives. This includes talent management, employee experience, inclusion and diversity, wellbeing, learning and development, and total rewards. Placid also oversees Teva’s Global Corporate Affairs function, which leads internal and external communications and drives Teva’s reputation and brand.

As a seasoned Human Resources executive, Placid brings a wealth of experience in talent management, leadership development, and organizational effectiveness. He excels in building high-performing teams, fostering inclusive workplaces, and enhancing employee engagement and performance. Placid is driven by both data and outcomes and is dedicated to unleashing the full potential of people and teams.

Before joining Teva, Placid spearheaded transformative HR initiatives in multinational corporations, including Unilever. His leadership and innovative approach resulted in significant improvements in workforce productivity and company culture.

Placid holds a combined degree in Business Administration and an MBA from ESADE Business School Barcelona, Spain, majoring in Marketing and International Business. Additionally, he has pursued executive education at institutions such as Harvard, Columbia, MIT, and INSEAD, in line with his philosophy of continuous learning.

What is Placid Jover's net worth?: The estimated net worth of Placid Jover is at least $192.31 thousand as of August 1st, 2025. Jover owns 6,774 shares of Teva Pharmaceutical Industries stock worth more than $192,314 as of December 5th. This net worth approximation does not reflect any other investments that Jover may own. Learn More about Placid Jover's net worth.
How do I contact Placid Jover?: The corporate mailing address for Jover and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Placid Jover's contact information.
Has Placid Jover been buying or selling shares of Teva Pharmaceutical Industries?: Placid Jover has not been actively trading shares of Teva Pharmaceutical Industries within the last three months. Most recently, Placid Jover sold 6,053 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a transaction totalling $91,763.48. Following the completion of the sale, the insider now directly owns 6,774 shares of the company's stock, valued at $102,693.84. Learn More on Placid Jover's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Placid Jover (Insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), Matthew Shields (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 5 times. They sold a total of 551,001 shares worth more than $12,113,818.32. The most recent insider tranaction occured on November, 6th when Director Roberto Mignone sold 200,000 shares worth more than $4,822,000.00. Insiders at Teva Pharmaceutical Industries own 0.5% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/6/2025.

Placid Jover Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/1/2025	Sell	6,053	$15.16	$91,763.48	6,774

Placid Jover Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $28.39

$27.96

$28.46

50 Day Range

MA: $22.28

$18.30

$28.39

2 Week Range

Now: $28.39

$12.47

$28.46

Volume

11,018,001 shs

Average Volume

11,645,990 shs

Market Capitalization

$32.56 billion

P/E Ratio

47.32

Dividend Yield

N/A

Beta

0.67